cGAMP or STING agonists also show an enhanced antitumor response when combined with radiotherapy, chemotherapy, immune checkpoint inhibitors (PD-1 or CTLA4), or tumor vaccines (Deng et al., 2014; Fu et al., 2015; Wang et al., 2017a). This evidence concerns the gene STING1 and neoplasm.